315220-61-2

Upstream product

• 149862-39-5 7-Trifluoromethanesulfonyloxy-hept-5-ynoic acid methyl ester 
• 315220-58-7 (3R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-3-[(E)-(S)-3-(tert-butyl-dimethyl-silanyloxy)-oct-1-enyl]-1-trimethylsilanyloxy-cyclohexene 
• 31776-12-2 methyl 7-iodohept-5-ynoate 
• 164577-42-8 <(4R)-(+)-tert-Butoxydimethylsiloxy>-2-cyclohexen-1-on 
• 50999-83-2 (S)-tert-butyl-(1-ethynylhexyloxy)dimethylsilane 
• 50781-91-4 methyl 7-hydroxy-5-heptynoate 

Downstream Products

• 315220-65-6 (Z)-7-{(1R,2R,3R)-3-(tert-Butyl-dimethyl-silanyloxy)-2-[(E)-(S)-3-(tert-butyl-dimethyl-silanyloxy)-oct-1-enyl]-6-oxo-cyclohexyl}-hept-5-enoic acid methyl ester 

Relevant academic research and scientific papers

Cyclohexyl prostaglandin analogs as EP4-receptor agonists

The invention relates to the use of novel cyclohexyl analogues of E-type prostaglandins as EP4 agonists, in general, and, in particular as ocular hypotensives. The cyclohexyl analogues used in accordance with the invention are represented by th

Solution- and soluble-polymer supported asymmetric syntheses of six-membered ring prostanoids

An asymmetric synthesis of prostanoids containing a six-membered ring core structure (11a-homoprostaglandins), both in solution and using non-cross-linked polystyrene (NCPS) as a soluble support, was developed. Target molecule 1 was generated in a converg